Table 1.
Meta-analyses included in study and their respective coding, by subcategory, for financial ties, quality score, results, and conclusions
| Web reference No | Financial ties* | Quality score† | Results | Conclusions |
|---|---|---|---|---|
| w1 | No statement | 1 | Neither in favour nor against | Neutral |
| w2 | One company | 2 | Unclear | In favour of study drug |
| w3 | No statement | 0 | Neither in favour nor against | In favour of study drug |
| w4 | No statement | 10 | In favour of study drug | In favour of study drug |
| w5 | No statement | 10 | Neither in favour nor against | Neutral |
| w6 | Non-profit | 6 | In favour of study drug | In favour of study drug |
| w7 | One company | 8 | In favour of study drug | In favour of study drug |
| w8 | No statement | 16 | In favour of study drug | In favour of study drug |
| w9 | One company | 3 | In favour of study drug | In favour of study drug |
| w10 | One company | 6 | Neither in favour nor against | In favour of study drug |
| w11 | Non-profit | 1 | In favour of study drug | In favour of study drug |
| w12 | Non-profit | 7 | Other | Neutral |
| w13 | No statement | 9 | In favour of study drug | In favour of study drug |
| w14 | Multiple companies | 16 | In favour of study drug | In favour of study drug |
| w15 | One company | 3 | In favour of study drug | In favour of study drug |
| w16 | One company, non-profit | 10 | Against study drug | Against study drug |
| w17 | Non-profit | 12 | In favour of study drug | In favour of study drug |
| w18 | One company | 6 | Unclear | In favour of study drug |
| w19 | One company | 0 | Unclear | In favour of study drug |
| w20 | One company | 4 | In favour of study drug | In favour of study drug |
| w21 | One company | 7 | In favour of study drug | In favour of study drug |
| w22 | One company | 5 | In favour of study drug | In favour of study drug |
| w23 | Non-profit | 4 | Neither in favour nor against | In favour of study drug |
| w24 | No statement | 10 | In favour of study drug | In favour of study drug |
| w25 | One company | 5 | In favour of study drug | In favour of study drug |
| w26 | Non-profit | 10 | In favour of study drug | In favour of study drug |
| w27 | One company | 3 | Unclear | In favour of study drug |
| w28 | One company | 1 | In favour of study drug | In favour of study drug |
| w29 | One company | 5 | Unclear | In favour of study drug |
| w30 | One company | 2 | Neither in favour nor against | In favour of study drug |
| w31 | Multiple companies, non-profit | 1 | Unclear | Neutral |
| w32 | One company | 4 | Against study drug | Against study drug |
| w33 | One company | 13 | In favour of study drug | In favour of study drug |
| w34 | Non-profit | 16 | In favour of study drug | In favour of study drug |
| w35 | One company | 0 | In favour of study drug | In favour of study drug |
| w36 | No statement | 6 | Neither in favour nor against | In favour of study drug |
| w37 | Non-profit | 8 | In favour of study drug | In favour of study drug |
| w38 | Non-profit | 9 | In favour of study drug | In favour of study drug |
| w39 | No statement | 7 | In favour of study drug | In favour of study drug |
| w40 | One company | 1 | In favour of study drug | In favour of study drug |
| w41 | One company | 9 | In favour of study drug | In favour of study drug |
| w42 | Non-profit | 10 | In favour of study drug | In favour of study drug |
| w43 | No statement | 1 | Neither in favour nor against | Neutral |
| w44 | No statement | 10 | Neither in favour nor against | Neutral |
| w45 | One company | 8 | Unclear | In favour of study drug |
| w46 | Non-profit | 10 | Unclear | Neutral |
| w47 | Other only‡ | 9 | In favour of study drug | In favour of study drug |
| w48 | Multiple companies | 4 | Against study drug | Against study drug |
| w49 | Non-profit | 9 | Neither in favour nor against | Neutral |
| w50 | One company | 11 | In favour of study drug | In favour of study drug |
| w51 | Non-profit | 14 | In favour of study drug | In favour of study drug |
| w52 | One company, non-profit | 7 | In favour of study drug | In favour of study drug |
| w53 | Non-profit | 5 | In favour of study drug | In favour of study drug |
| w54 | Non-profit | 12 | In favour of study drug | In favour of study drug |
| w55 | No statement | 5 | In favour of study drug | In favour of study drug |
| w56 | No statement | 15 | Other | Other |
| w57 | One company | 1 | Unclear | In favour of study drug |
| w58 | One company | 5 | Neither in favour nor against | In favour of study drug |
| w59 | One company | 0 | In favour of study drug | In favour of study drug |
| w60 | Non-profit | 8 | In favour of study drug | In favour of study drug |
| w61 | No statement | 10 | In favour of study drug | In favour of study drug |
| w62 | Non-profit | 9 | In favour of study drug | In favour of study drug |
| w63 | No statement | 13 | In favour of study drug | In favour of study drug |
| w64 | One company | 5 | In favour of study drug | In favour of study drug |
| w65 | No statement | 7 | In favour of study drug | In favour of study drug |
| w66 | Non-profit | 0 | In favour of study drug | Unclear |
| w67 | One company | 7 | In favour of study drug | In favour of study drug |
| w68 | One company | 8 | In favour of study drug | In favour of study drug |
| w69 | Non-profit | 2 | In favour of study drug | In favour of study drug |
| w70 | Non-profit | 7 | In favour of study drug | In favour of study drug |
| w71 | Multiple companies | 5 | In favour of study drug | In favour of study drug |
| w72 | Multiple companies | 0 | Neither in favour nor against | In favour of study drug |
| w73 | One company | 0 | Neither in favour nor against | In favour of study drug |
| w74 | Multiple companies | 11 | In favour of study drug | In favour of study drug |
| w75 | One company | 3 | Neither in favour nor against | In favour of study drug |
| w76 | None§ | 17 | In favour of study drug | In favour of study drug |
| w77 | Multiple companies, non-profit | 10 | In favour of study drug | In favour of study drug |
| w78 | One company | 0 | Neither in favour nor against | In favour of study drug |
| w79 | No statement | 13 | In favour of study drug | In favour of study drug |
| w80 | Non-profit | 12 | In favour of study drug | In favour of study drug |
| w81 | One company | 3 | In favour of study drug | In favour of study drug |
| w82 | One company | 9 | Neither in favour nor against | In favour of study drug |
| w83 | Multiple companies | 14 | In favour of study drug | In favour of study drug |
| w84 | Multiple companies | 13 | Against study drug | Against study drug |
| w85 | Multiple companies | 12 | In favour of study drug | In favour of study drug |
| w86 | Non-profit | 2 | Unclear | Neutral |
| w87 | No statement | 7 | Against study drug | Against study drug |
| w88 | One company | 11 | In favour of study drug | In favour of study drug |
| w89 | One company | 1 | Unclear | In favour of study drug |
| w90 | Multiple companies | 1 | In favour of study drug | In favour of study drug |
| w91 | No statement | 2 | Neither in favour nor against | Neutral |
| w92 | Multiple companies, non-profit | 13 | In favour of study drug | In favour of study drug |
| w93 | One company | 3 | In favour of study drug | In favour of study drug |
| w94 | No statement | 1 | Neither in favour nor against | In favour of study drug |
| w95 | Multiple companies, non-profit | 14 | In favour of study drug | In favour of study drug |
| w96 | Multiple companies | 0 | Unclear | Against study drug |
| w97 | One company | 16 | Neither in favour nor against | Neutral |
| w98 | One company | 17 | In favour of study drug | In favour of study drug |
| w99 | One company | 7 | In favour of study drug | In favour of study drug |
| w100 | Non-profit | 5 | In favour of study drug | In favour of study drug |
| w101 | One company | 14 | In favour of study drug | In favour of study drug |
| w102 | Non-profit | 9 | In favour of study drug | In favour of study drug |
| w103 | One company | 3 | In favour of study drug | In favour of study drug |
| w104 | One company | 3 | Neither in favour nor against | In favour of study drug |
| w105 | No statement | 14 | Neither in favour nor against | Neutral |
| w106 | No statement | 9 | In favour of study drug | In favour of study drug |
| w107 | Multiple companies | 0 | Unclear | In favour of study drug |
| w108 | One company | 2 | In favour of study drug | In favour of study drug |
| w109 | No statement | 6 | In favour of study drug | In favour of study drug |
| w110 | Multiple companies | 2 | In favour of study drug | In favour of study drug |
| w111 | One company | 0 | Unclear | Unclear |
| w112 | One company | 1 | Neither in favour nor against | Neutral |
| w113 | Multiple companies | 4 | In favour of study drug | In favour of study drug |
| w114 | One company, non-profit | 8 | Neither in favour nor against | Neutral |
| w115 | One company, non-profit | 2 | In favour of study drug | In favour of study drug |
| w116 | Multiple companies | 12 | Neither in favour nor against | In favour of study drug |
| w117 | One company | 2 | Unclear | In favour of study drug |
| w118 | Multiple companies, non-profit | 10 | In favour of study drug | In favour of study drug |
| w119 | Non-profit | 6 | Unclear | Neutral |
| w120 | One company | 0 | Other | In favour of study drug |
| w121 | No statement | 7 | In favour of study drug | In favour of study drug |
| w122 | Non-profit | 16 | In favour of study drug | In favour of study drug |
| w123 | One company | 1 | In favour of study drug | In favour of study drug |
| w124 | One company | 10 | In favour of study drug | In favour of study drug |
*Subcategories of “one company, non-profit” and “multiple companies, non-profit” were combined for purposes of calculating descriptive statistics in table 5, as together they only represent nine meta-analyses.
†Minimum score=0, maximum score=18.
‡One meta-analysis in this predefined subcategory (w47) was included in “non-profit” subcategory for purposes of calculating descriptive statistics in table 5.
§One meta-analysis in this predefined subcategory (w76) was included in “no statement” subcategory for purposes of calculating descriptive statistics in table 5.